Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting

D. Santini, V. Virzi, M. E. Fratto, F. Bertoldo, R. Sabbatini, R. Berardi, N. Calipari, D. Ottaviani, T. Ibrahim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

New emerging data suggest that bisphosphonates may exert antitumor properties. Preclinical studies have demonstrated that zoledronic acid (ZA) can induce direct and indirect antitumor activities such as inhibition of angiogenesis, invasion and adhesion of tumor cells, and overall tumor progression, stimulation of adoptive and innate immunity and emerging evidence suggests that the use of these agents may prevent the development of skeletal and extra skeletal metastases. This review will critically describe the new growing evidence of antitumor activity exerted by bisphosphonates in cancer patients, both in metastatic disease and in the adjuvant setting. The effects of bisphosphonates on survival in metastatic cancer patients will be described and evidence from retrospective analyses and prospective studies will be critically reported. The early evidence from prospective analyses of survival impact by ZA in the adjuvant setting in breast cancer will be discussed together with the recently published results of the ABCSG-12 study. A new "era" for bisphosphonates in the oncological setting is opening. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of adjuvant and metastatic cancer therapies.

Original languageEnglish
Pages (from-to)46-54
Number of pages9
JournalCurrent Cancer Drug Targets
Volume10
Issue number1
DOIs
Publication statusPublished - Feb 2010

Fingerprint

zoledronic acid
Antineoplastic Agents
Diphosphonates
Neoplasms
Adaptive Immunity
Survival Analysis
Innate Immunity
Cell Adhesion
Retrospective Studies
Prospective Studies
Breast Neoplasms
Neoplasm Metastasis

Keywords

  • Antitumor activity
  • Humans
  • Phase III trials
  • Survival
  • Zoledronic acid

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. / Santini, D.; Virzi, V.; Fratto, M. E.; Bertoldo, F.; Sabbatini, R.; Berardi, R.; Calipari, N.; Ottaviani, D.; Ibrahim, T.

In: Current Cancer Drug Targets, Vol. 10, No. 1, 02.2010, p. 46-54.

Research output: Contribution to journalArticle

Santini, D, Virzi, V, Fratto, ME, Bertoldo, F, Sabbatini, R, Berardi, R, Calipari, N, Ottaviani, D & Ibrahim, T 2010, 'Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting', Current Cancer Drug Targets, vol. 10, no. 1, pp. 46-54. https://doi.org/10.2174/156800910790980223
Santini, D. ; Virzi, V. ; Fratto, M. E. ; Bertoldo, F. ; Sabbatini, R. ; Berardi, R. ; Calipari, N. ; Ottaviani, D. ; Ibrahim, T. / Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. In: Current Cancer Drug Targets. 2010 ; Vol. 10, No. 1. pp. 46-54.
@article{a48a75561eac4791a17d7f0c6a3f6983,
title = "Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting",
abstract = "New emerging data suggest that bisphosphonates may exert antitumor properties. Preclinical studies have demonstrated that zoledronic acid (ZA) can induce direct and indirect antitumor activities such as inhibition of angiogenesis, invasion and adhesion of tumor cells, and overall tumor progression, stimulation of adoptive and innate immunity and emerging evidence suggests that the use of these agents may prevent the development of skeletal and extra skeletal metastases. This review will critically describe the new growing evidence of antitumor activity exerted by bisphosphonates in cancer patients, both in metastatic disease and in the adjuvant setting. The effects of bisphosphonates on survival in metastatic cancer patients will be described and evidence from retrospective analyses and prospective studies will be critically reported. The early evidence from prospective analyses of survival impact by ZA in the adjuvant setting in breast cancer will be discussed together with the recently published results of the ABCSG-12 study. A new {"}era{"} for bisphosphonates in the oncological setting is opening. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of adjuvant and metastatic cancer therapies.",
keywords = "Antitumor activity, Humans, Phase III trials, Survival, Zoledronic acid",
author = "D. Santini and V. Virzi and Fratto, {M. E.} and F. Bertoldo and R. Sabbatini and R. Berardi and N. Calipari and D. Ottaviani and T. Ibrahim",
year = "2010",
month = "2",
doi = "10.2174/156800910790980223",
language = "English",
volume = "10",
pages = "46--54",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting

AU - Santini, D.

AU - Virzi, V.

AU - Fratto, M. E.

AU - Bertoldo, F.

AU - Sabbatini, R.

AU - Berardi, R.

AU - Calipari, N.

AU - Ottaviani, D.

AU - Ibrahim, T.

PY - 2010/2

Y1 - 2010/2

N2 - New emerging data suggest that bisphosphonates may exert antitumor properties. Preclinical studies have demonstrated that zoledronic acid (ZA) can induce direct and indirect antitumor activities such as inhibition of angiogenesis, invasion and adhesion of tumor cells, and overall tumor progression, stimulation of adoptive and innate immunity and emerging evidence suggests that the use of these agents may prevent the development of skeletal and extra skeletal metastases. This review will critically describe the new growing evidence of antitumor activity exerted by bisphosphonates in cancer patients, both in metastatic disease and in the adjuvant setting. The effects of bisphosphonates on survival in metastatic cancer patients will be described and evidence from retrospective analyses and prospective studies will be critically reported. The early evidence from prospective analyses of survival impact by ZA in the adjuvant setting in breast cancer will be discussed together with the recently published results of the ABCSG-12 study. A new "era" for bisphosphonates in the oncological setting is opening. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of adjuvant and metastatic cancer therapies.

AB - New emerging data suggest that bisphosphonates may exert antitumor properties. Preclinical studies have demonstrated that zoledronic acid (ZA) can induce direct and indirect antitumor activities such as inhibition of angiogenesis, invasion and adhesion of tumor cells, and overall tumor progression, stimulation of adoptive and innate immunity and emerging evidence suggests that the use of these agents may prevent the development of skeletal and extra skeletal metastases. This review will critically describe the new growing evidence of antitumor activity exerted by bisphosphonates in cancer patients, both in metastatic disease and in the adjuvant setting. The effects of bisphosphonates on survival in metastatic cancer patients will be described and evidence from retrospective analyses and prospective studies will be critically reported. The early evidence from prospective analyses of survival impact by ZA in the adjuvant setting in breast cancer will be discussed together with the recently published results of the ABCSG-12 study. A new "era" for bisphosphonates in the oncological setting is opening. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of adjuvant and metastatic cancer therapies.

KW - Antitumor activity

KW - Humans

KW - Phase III trials

KW - Survival

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=77950389836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950389836&partnerID=8YFLogxK

U2 - 10.2174/156800910790980223

DO - 10.2174/156800910790980223

M3 - Article

C2 - 20088792

AN - SCOPUS:77950389836

VL - 10

SP - 46

EP - 54

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 1

ER -